cell therapyPharmaceutical InformationUpdated on Jul 23, 2018 View more like this | Visit SHIRLEY, NY | Contact Cathy Miller |
After the success of PD-1/PDL-1 inhibitors on the market, many researchers are turning their attention to CAR-T therapy, which treated leukemia and lymphoma successfully.
In a CAR-T therapy, T cells from a patient was extracted and then genetically modified to express a Chimeric Antigen Receptor (CAR) on their cell membrane and expanded in vitro. This receptor consists of an external target-binding domain designed to recognize a specific tumor antigen and an internal activation domain responsible for activating the T cell when the CAR-T binds its target. Finally, these T cells are reinfused into the patient to kill the cancer cells.
Immunotherapies using checkpoint inhibitors such as of PD-1/PDL-1 inhibitors have already been proven successful in clinical trials. They block a mechanism that tumor cells use to hide from immune system. CAR-T cells therapy goes one step further by engineering the T cells themselves to enhance the response from the immune system against tumor cells.
In a CAR-T therapy, T cells from a patient was extracted and then genetically modified to express a Chimeric Antigen Receptor (CAR) on their cell membrane and expanded in vitro. This receptor consists of an external target-binding domain designed to recognize a specific tumor antigen and an internal activation domain responsible for activating the T cell when the CAR-T binds its target. Finally, these T cells are reinfused into the patient to kill the cancer cells.
Immunotherapies using checkpoint inhibitors such as of PD-1/PDL-1 inhibitors have already been proven successful in clinical trials. They block a mechanism that tumor cells use to hide from immune system. CAR-T cells therapy goes one step further by engineering the T cells themselves to enhance the response from the immune system against tumor cells.
